Results 61 to 70 of about 20,319 (246)

TIVMETIX OD – A Sulfonylurea-based Herbicide with improved efficacy through novel oil dispersion (OD) formulation technology

open access: yesJulius-Kühn-Archiv, 2016
TIVMETIX OD is a novel oil dispersion (OD) post-emergence herbicide for the spring application (BBCH 13-39) against broad-leafed weeds in all varieties of winter and spring wheat, winter and spring barley, winter rye and triticale.
Gimeno, Barbara   +4 more
doaj   +1 more source

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT‐1 and SURMOUNT‐2 Trials

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Obesity affects over 800 million people globally and is associated with complications including cardiovascular disease and type 2 diabetes (T2D). Early response to weight loss interventions may help optimize achievement of individual treatment goals.
Alexander Kokkinos   +7 more
wiley   +1 more source

Recent Advances in Neonatal Diabetes

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2020
Amanda Dahl, Seema Kumar Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USACorrespondence: Seema KumarDivision of Pediatric Endocrinology and Metabolism, Department of ...
Dahl A, Kumar S
doaj  

Resistência de amendoim-bravo aos herbicidas inibidores da enzima acetolactato sintase Wild poinsettia resistance to acetolactate synthase inhibitor herbicides

open access: yesPlanta Daninha, 1999
O controle contínuo de plantas daninhas através da aplicação de herbicidas que apresentam atividade em um único local de ação nas plantas favorece a seleção de biótipos resistentes a estes herbicidas, em certas espécies vegetais.
Ribas A. Vidal, Aldo Merotto Jr.
doaj   +1 more source

One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin‐Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin‐Requiring Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear.
Ninoschka C. D'Souza   +7 more
wiley   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux   +14 more
wiley   +1 more source

Sulfonylureas.

open access: yesJPMA. The Journal of the Pakistan Medical Association, 2015
This review describes the basic and clinical pharmacology of sulfonylureas. It undertakes a balanced assessment of the advantages and limitations of sulfonylureas, and compares the use of various sulfonylureas in different clinical situations. The authors suggest pragmatic guidance to facilitate safe and effective use of this class of drugs, and thus ...
Sanjay, Kalra, Yashdeep, Gupta
openaire   +1 more source

Importance of Hypercortisolism in BP Control, Cardiovascular Risk and in Patients With Difficult‐to‐Control Hypertension: An Overview for Primary Care Physicians

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension remains one of the most prevalent and consequential modifiable cardiovascular risk factors worldwide, affecting approximately 1.28 billion adults globally and nearly half of the United States population. Despite the availability of effective therapies, optimal blood pressure control is achieved in fewer than one in four ...
Matthew A. Cavender
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy